Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 12 lead Electrocardiogram Clear all
Withdrawn Phase 2 Interventional

Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06398587
View directory record Official record
Conditions
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
Interventions
Onvansertib, Gemcitabine, Nab-paclitaxel, Electrocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Biospecimen Collection, Computed Tomography
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 18, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Completed Not applicable Interventional

The SMART-LV Pilot Study

NCT05630170
View directory record Official record
Conditions
Left Ventricular Systolic Dysfunction
Interventions
AI-ECG
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Terminated Not applicable Interventional Results available

Low-dose Epinephrine Infusion Tests in Adolescent and Pediatric Patients

NCT00548886
View directory record Official record
Conditions
Congenital Disorders
Interventions
Epinephrine
Drug
Lead sponsor
Emory University
Other
Eligibility
3 Years to 18 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 29, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Topical Application of Cocaine HCl 4% and 10% on Safety and Efficacy in Local (Topical) Anesthesia

NCT01746940
View directory record Official record
Conditions
Diagnostic, Procedures and Surgeries on or Through Accessible Mucous Membranes, of the Nasal Cavities
Interventions
Cocaine HCl 4% Topical Solution, Cocaine HCl 10% Topical Solution, Placebo Topical Solution
Drug
Lead sponsor
Lannett Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
2
States / cities
Bridgeport, Connecticut • Plano, Texas
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 29, 2026, 9:09 AM EDT
Recruiting Not applicable Interventional

A Study Of Heart Disease Using AI-Enabled Electrocardiography And Focused Cardiac Ultrasound

NCT07351656
View directory record Official record
Conditions
Heart Disease
Interventions
Focused Cardiac Ultrasound, 6-Lead AI-ECG, 12-Lead AI-ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
19,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 29, 2026, 9:09 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

BMS-986253 in Myelodysplastic Syndromes

NCT05148234
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Decitabine, Deoxyribonucleic acid (DNA) methyltransferase inhibitors (DNMTi) Cedazuridine, BMS-986253, Bone Marrow Biopsy, Bone Marrow Aspiration, ECG
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 29, 2026, 9:09 AM EDT
Terminated Phase 1 Interventional

Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas

NCT03971734
View directory record Official record
Conditions
High Grade Glioma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Glioblastoma
Interventions
Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg, Regadensoson 0.4mg, Regadensoson 0.7mg, Regadensoson 1.0mg, Regadensoson 1.4mg
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Sep 29, 2026, 9:09 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Thrombosis

NCT03830320
View directory record Official record
Conditions
Atrial Fibrillation, COVID-19, Cancer, Thrombosis
Interventions
[64Cu]FBP8, PET/MR, Blood Collection, Electrocardiogram
Drug · Device · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 29, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparison of a Novel 12-Lead Wireless Electrocardiogram (ECG) and a Standard Wired ECG

NCT00998842
View directory record Official record
Conditions
Healthy
Interventions
Recom Model 100, GE 5000 ECG Monitor System
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 3, 2009 · Synced Sep 29, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparative Trial of Standard 12 Lead ECG to the 12 Lead ECG Glove to Assess Cardiac Electrical Function

NCT01218334
View directory record Official record
Conditions
Cardiac Electrical Function
Interventions
12 Lead Glove
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 29, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Intravenous Zanamivir on Cardiac Conduction in Healthy Volunteers

NCT01353729
View directory record Official record
Conditions
Influenza, Human
Interventions
600 mg zanamivir + moxifloxacin placebo, 1200 mg zanamivir + moxifloxacin placebo, zanamivir placebo + moxifloxacin placebo, zanamivir placebo + 400 mg moxifloxacin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2017 · Synced Sep 29, 2026, 9:09 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers

64Cu-LLP2A for Imaging Multiple Myeloma

NCT03804424
View directory record Official record
Conditions
Multiple Myeloma
Interventions
64Cu-LLP2A, PET/MR, Blood samples for serum stability, Blood samples for metabolite analysis, Urine sample, Tumor biopsy, Electrocardiogram, PET/CT
Drug · Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Clinical Validation of the AliveCor Kardia 12L and 6L Devices

NCT05053243
View directory record Official record
Conditions
Arrhythmia
Interventions
Kardia 12L
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 90 Years
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Clinical Validation and Safety of the AC 12L ECG System Against a Standard of Care 12-Lead ECG (AC 12L ECG)

NCT05617001
View directory record Official record
Conditions
Arrhythmia
Interventions
Kardia 12L
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Recruiting No phase listed Observational

AK+ Guard™ Pilot Study in Chronic Kidney Disease: Outpatient Diagnostic Accuracy and Remote Monitoring

NCT07210021
View directory record Official record
Conditions
Hyperkalemia, Chronic Kidney Disease (Stage 3-4)
Interventions
AK+ Guard™ ECG Application
Device
Lead sponsor
AccurKardia, Inc.
Industry
Eligibility
22 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Sep 29, 2026, 9:09 AM EDT
Active, not recruiting No phase listed Observational

A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's

NCT06290570
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
12-Lead ECG, Apple Smart Watch Single Lead ECG, AliveCor KardiaMobile 6-Lead ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 29, 2026, 9:09 AM EDT
Active, not recruiting No phase listed Observational

Study of Cardiopulmonary Exercise Testing in Women Who Have HER2-Positive Breast Cancer With Mild Cardiotoxicity

NCT05036252
View directory record Official record
Conditions
Breast Cancer, HER2-positive Breast Cancer, HER2-positive Metastatic Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Breast Cancer Stage IV, Cardiotoxicity
Interventions
Cardiopulmonary Exercise Test, Echocardiogram, Echocardiography
Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 29, 2026, 9:09 AM EDT
Not listed Not applicable Interventional

Multi-lead ECG to Effectively Optimize Resynchronization Devices: New CRT Recipients

NCT04083690
View directory record Official record
Conditions
Heart Failure, Systolic
Interventions
Reprogramming of CRT Device Settings to Optimal Electrical Synchrony
Device
Lead sponsor
Allina Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Sep 29, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Effect of Therapeutic and Supratherapeutic Oral Doses of GSK3640254 on Cardiac Conduction Compared to Placebo and a Single Oral Dose of Moxifloxacin

NCT04563845
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3640254, Placebo, Moxifloxacin
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Sep 29, 2026, 9:09 AM EDT
Completed No phase listed Observational

A Multi-Center Study of Detection of Low Ventricular Ejection Fraction

NCT04963218
View directory record Official record
Conditions
Cardiac Disease
Interventions
AI Algorithm to detect LVEF in ECG
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 99 Years
Enrollment
16,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Boston, Massachusetts • The Bronx, New York • Rapid City, South Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Sep 29, 2026, 9:09 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects

NCT01297062
View directory record Official record
Conditions
Healthy Subjects
Interventions
Exenatide, Moxifloxacin, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Daytona Beach, Florida • Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Sep 29, 2026, 9:09 AM EDT
Recruiting Not applicable Interventional

Cardiac Resynchronization Therapy Delivery Guided Non-Invasive Electrical and Venous Anatomy Assessment

NCT05327062
View directory record Official record
Conditions
Cardiac Resynchronization Therapy, Chronic Heart Failure, Left Bundle-Branch Block
Interventions
CRT implantation guided by XSpline, a non-invasive electrical and venous anatomy assessment
Device
Lead sponsor
XSpline S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Chicago, Illinois • Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

NCT02615054
View directory record Official record
Conditions
Trastuzumab Cardiotoxicity, HER2-Positive Breast Cancer Survivors
Interventions
2D Echocardiogram, Cardiopulmonary exercise testing and post-CPET cardiac function
Device
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Sep 29, 2026, 9:09 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Everbeat Ring ECG Clinical Concordance Study

NCT05469542
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
Everbeat Ring
Device
Lead sponsor
Grektek Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 29, 2026, 9:09 AM EDT